Volume 6 Issue 1
Jan.  2015
Turn off MathJax
Article Contents

doi: 10.3969/j.issn.1674-9081.2015.01.009
  • Received Date: 2014-02-25
  • Publish Date: 2015-01-30
  • loading
  • [1] Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France-Results from a national registry[J]. Am J Resp Crit Care, 2006, 173:1023-1030. doi:  10.1164/rccm.200510-1668OC
    [2] Ling Y, Johnson MK, Kiely DG, et al. Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension results from the pulmonary hypertension registry of the United Kingdom and Ireland[J]. Am J Resp Crit Care, 2012, 186:790-796. doi:  10.1164/rccm.201203-0383OC
    [3] Farber HW, Loscalzo J. Pulmonary arterial hypertension[J]. N Engl J Med, 2004, 351:1655-1665. doi:  10.1056/NEJMra035488
    [4] Galie N, Simonneau G. The fifth world symposium on pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62:D1-D3. doi:  10.1016/j.jacc.2013.10.030
    [5] Preston IR. Properly diagnosing pulmonary arterial hypertension[J]. Am J Cardiol, 2013, 111:2C-9C. doi:  10.1016/j.amjcard.2013.01.318
    [6] Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62:D34-D41. doi:  10.1016/j.jacc.2013.10.029
    [7] Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension[J]. J Am Coll Cardiol, 2013, 62:D42-D50. doi:  10.1016/j.jacc.2013.10.032
    [8] Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling[J]. J Am Coll Cardiol, 2009, 54:S10-S19. doi:  10.1016/j.jacc.2009.04.006
    [9] Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2009, 54:S20-S31. doi:  10.1016/j.jacc.2009.04.018
    [10] Soubrier F, Chung WK, Machado R, et al. Genetics and genomics of pulmonary arterial hypertension[J]. J Am Coll Cardiol, 2013, 62:D13-D21. doi:  10.1016/j.jacc.2013.10.035
    [11] Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension:current understanding and future directions[J]. J Am Coll Cardiol, 2004, 43:33S-39S. doi:  10.1016/j.jacc.2004.02.028
    [12] Loyd JE. Pulmonary arterial hypertension:insights from genetic studies[J]. Proc Am Thorac Soc, 2011, 8:154-157. doi:  10.1513/pats.201007-047MS
    [13] International PPHC, Lane KB, Machado RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension[J]. Nature Genet, 2000, 26:81-84. doi:  10.1038/79226
    [14] Deng Z, Morse JH, Moore KJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-Ⅱ gene[J]. Am J Hum Genet, 2000, 67:737-744. doi:  10.1086/303059
    [15] Trembath RC. Mutations in the TGF-beta type 1 receptor, ALK1, in combined primary pulmonary hypertension and hereditary heamrrhagic lalangiectasis, implies pathway specificity[J]. J Heart Lung Transplant, 2001, 20:175.
    [16] Morisaki H, Nakanishi N, Morisaki T. BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension[J]. Hum Mutat, 2004, 23:632.
    [17] Machado RD, Aldred MA, Patel B, et al. Mutations of the TGF-beta type Ⅱ receptor BMPR2 in pulmonary arterial hypertension[J]. Hum Mutat, 2006, 27:121-132. doi:  10.1002/humu.20285
    [18] Nicod LP. The endothelium and genetics in pulmonary arterial hypertension[J]. Swiss Med, 2007, 137:437-442.
    [19] Nasim MT, Ogo T, Chowdhury HM, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension[J]. Hum Mutat, 2011, 32:1385-1389. doi:  10.1002/humu.21605
    [20] Chaouat A, Simonneau G, Weitzenblum E, et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension[J]. Thorax, 2004, 59:446-448. doi:  10.1136/thx.2003.11890
    [21] Harrison RE, Flanagan JA, Sankelo M, et al. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia[J]. J Med Genet, 2003, 40:865-871. doi:  10.1136/jmg.40.12.865
    [22] Attisano L, Wrana JL. Signal transduction by the TGF-beta superfamily[J]. Science, 2002, 296:1646-1647. doi:  10.1126/science.1071809
    [23] Newman JH, Phillips JA 3rd, Loyd JE. Narrative review:the enigma of pulmonary arterial hypertension:new insights from genetic studies[J]. Ann Intern Med, 2008, 148:278-283. doi:  10.7326/0003-4819-148-4-200802190-00006
    [24] Eickelberg O, Morty RE. Transforming growth factor beta/bone morphogenic protein signaling in pulmonary arterial hypertension:remodeling revisited[J]. Trends Cardiovasc Med, 2007, 17:263-269. doi:  10.1016/j.tcm.2007.09.003
    [25] Atkinson C, Machado R, Thomson JR, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type Ⅱ bone morphogenetic protein receptor[J]. Circulation, 2002, 105:1672-1678. doi:  10.1161/01.CIR.0000012754.72951.3D
    [26] Elliott CG. Genetics of pulmonary arterial hypertension:current and future implications[J]. Semin Respir Critical Care Med, 2005, 26:365-371. doi:  10.1055/s-2005-916150
    [27] Machado RD, Pauciulo MW, Morgan NV, et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension[J]. Am J Hum Genet, 2001, 68:92-102. doi:  10.1086/316947
    [28] Morrell NW, Yang X, Morgan N, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins[J]. Circulation, 2001, 104:790-795. doi:  10.1161/hc3201.094152
    [29] Phillips JA, Stanton KC, Austin ED, et al. Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension[J]. Genet Med, 2008, 10:359-365. doi:  10.1097/GIM.0b013e318172dcdf
    [30] Austin ED, Phillips JA, Cogan JD, et al. Truncating and missense BMPR2 mutations differentially affect the severity of heritable pulmonary arterial hypertension[J]. Respir Res, 2009, 10:87. doi:  10.1186/1465-9921-10-87
    [31] Austin ED, Cogan JD, Hamid R, et al. Alterations in oestrogen metabolism:implications for higher penetrance of familial pulmonary arterial hypertension in females[J]. Eur Respir J, 2009, 34:1093-1099. doi:  10.1183/09031936.00010409
    [32] Rodriguez-Murillo L, Subaran R, Marathe S, et al. Novel loci interacting epistatically with bone morphogenetic protein receptor 2 cause familial pulmonary arterial hypertension[J]. J Heart Lung Transpl, 2010, 29:174-180. doi:  10.1016/j.healun.2009.08.022
    [33] Best DH, Austin ED, Elliott CG. Genetics of pulmonary hypertension[J]. Curr Opin Cardiol, 2014, 29:520-527. doi:  10.1097/HCO.0000000000000105
    [34] Eddahibi S, Humbert M, Darmon M, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension[J]. J Clin Invest, 2001, 108:1141-1150. doi:  10.1172/JCI200112805
    [35] Eddahibi S, Adnot S. Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis:lessons for the future in pathogenesis[J]. Respir Res, 2002, 3:9.
    [36] Zhang H, Xu M, Xia J. Association between serotonin transporter (SERT) gene polymorphism and idiopathic pulmonary arterial hypertension:a meta-analysis and review of the literature[J]. Metabolism, 2013, 62:1867-1875. doi:  10.1016/j.metabol.2013.08.012
    [37] Germain M, Eyries M, Girerd B, et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension[J]. Nat Genet, 2013, 45:518-521. doi:  10.1038/ng.2581
    [38] Ma L, Chung WK. The genetic basis of pulmonary arterial hypertension[J]. Hum Genet, 2014, 133:471-479. doi:  10.1007/s00439-014-1419-3
    [39] Maloney JP, Stearman RS, Tripp-Addison ML, et al. Loss-of-function thrombospondin-1 mutations in familial pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302:L541-L554. doi:  10.1152/ajplung.00282.2011
    [40] Katta S, Vadapalli S, Sastry BK, et al. t-plasminogen activator inhibitor-1 polymorphism in idiopathic pulmonary arterial hypertension[J]. Indian J Hum Genet, 2008, 14:37-40. doi:  10.4103/0971-6866.44103
    [41] Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension[J]. Circ Res, 2014, 115:189-202. doi:  10.1161/CIRCRESAHA.115.303404
    [42] Habashi JP, Judge DP, Loeys BL, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome[J]. Science, 2006, 312:117-121. doi:  10.1126/science.1124287
    [43] Daniels CE, Wilkes MC, Edens M, et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis[J]. J Clin Invest, 2004, 114:1308-1316. doi:  10.1172/JCI200419603
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (135) PDF downloads(3) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return